Adalimumab effect on pain in hidradenitis suppurativa patients: systematic review and meta-analysis

Adalimumab effect on pain in hidradenitis suppurativa patients: systematic review and meta-analysis

Blog Article

Introduction: Pain is experienced by most patients with hidradenitis suppurativa (HS) and has a severe impact on their quality of life.Its management still presents a challenge.Adalimumab, a TNF-a antagonist, has shown promising results in HS-related pain reduction.Objectives: To aggregate and synthesize all existing evidence regarding the effect of adalimumab on HS-associated skin pain.

Methods: We identified original controlled and uncontrolled studies with participants receiving adalimumab, which included change in pain score post-treatment comparing to baseline as an endpoint.We searched MEDLINE, ScienceDirect, the Cochrane Library, ClinicalTrials.gov and International M BELTS Clinical Trials Registry Platform.The primary endpoint of our study was mean change (continuous variable) of pain scores at week 12 comparing to baseline.

Results: We performed LED Candle a meta-analysis of four randomized controlled trials (282 patients in the intervention group and 266 patients in the control group).Adalimumab brought about a 0.418 reduction in mean pain score at its worst with 95%CI [-0.588, -0.

248] and p = 0.000 at 12 weeks after treatment commencement.Four more studies were included in a qualitative synthesis, two of which reported statistically significant reduction in pain scores at week 12.Conclusions: Adalimumab could be prescribed more readily in cases of hidradenitis associated with significant skin pain.